CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
- PMID: 35565443
- PMCID: PMC9105267
- DOI: 10.3390/cancers14092314
CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
Abstract
CXCR4 is a G-Protein coupled receptor that is expressed nearly ubiquitously and is known to control cell migration via its interaction with CXCL12, the most ancient chemokine. The functions of CXCR4/CXCL12 extend beyond cell migration and involve the recognition and disposal of unhealthy or tumor cells. The CXCR4/CXCL12 axis plays a relevant role in shaping the tumor microenvironment (TME), mainly towards dampening immune responses. Notably, CXCR4/CXCL12 cross-signal via the T and B cell receptors (TCR and BCR) and co-internalize with CD47, promoting tumor cell phagocytosis by macrophages in an anti-tumor immune process called ImmunoGenic Surrender (IGS). These specific activities in shaping the immune response might be exploited to improve current immunotherapies.
Keywords: ACKR3; BCR; CD47; CXCL12; CXCR4; ImmunoGenic Surrender; TCR; immunotherapy.
Conflict of interest statement
M.E.B. is founder and part owner of HMGBiotech, and L.S.C. was supported by HMGBiotech. The other authors declare that they have no conflict of interest.
Figures


Similar articles
-
The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:541-563. doi: 10.1146/annurev-pharmtox-010919-023340. Epub 2020 Sep 21. Annu Rev Pharmacol Toxicol. 2021. PMID: 32956018
-
The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.Front Endocrinol (Lausanne). 2019 Aug 27;10:585. doi: 10.3389/fendo.2019.00585. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31507535 Free PMC article. Review.
-
CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.Front Oncol. 2021 Apr 15;11:591386. doi: 10.3389/fonc.2021.591386. eCollection 2021. Front Oncol. 2021. PMID: 33937018 Free PMC article. Review.
-
CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma.EMBO Mol Med. 2021 Jun 7;13(6):e12344. doi: 10.15252/emmm.202012344. Epub 2021 May 6. EMBO Mol Med. 2021. PMID: 33956406 Free PMC article.
-
CXCL12 Signaling in the Tumor Microenvironment.Adv Exp Med Biol. 2021;1302:51-70. doi: 10.1007/978-3-030-62658-7_5. Adv Exp Med Biol. 2021. PMID: 34286441 Review.
Cited by
-
Emerging Roles of Chemokines in Cancer Immunotherapy.Cancers (Basel). 2022 Jul 23;14(15):3593. doi: 10.3390/cancers14153593. Cancers (Basel). 2022. PMID: 35892852 Free PMC article.
-
Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.Ann Surg Oncol. 2024 Dec;31(13):9332-9343. doi: 10.1245/s10434-024-16053-7. Epub 2024 Aug 27. Ann Surg Oncol. 2024. PMID: 39190094
-
CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways.Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2416909121. doi: 10.1073/pnas.2416909121. Epub 2024 Dec 17. Proc Natl Acad Sci U S A. 2024. PMID: 39689179 Free PMC article.
-
Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy.Int J Mol Sci. 2022 Oct 18;23(20):12499. doi: 10.3390/ijms232012499. Int J Mol Sci. 2022. PMID: 36293358 Free PMC article. Review.
-
C-X-C Motif Chemokine 12 Was Identified as a Potential Gene Target in the Treatment of Crohn's Disease.Int J Gen Med. 2024 Dec 14;17:6219-6228. doi: 10.2147/IJGM.S487505. eCollection 2024. Int J Gen Med. 2024. PMID: 39703796 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials